Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06033950 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
A Phase 3 study of Heart Failure, sponsored by Colorado Prevention Center.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 2,600
- Enrollment target
- 8
- Study locations
NCT06033950 is a Phase 3 study of Heart Failure that is actively recruiting participants, run by Colorado Prevention Center. The registered enrollment target is 2,600 participants, above the 2,042-participant average among 397 other Heart Failure trials with a reported enrollment target (27% higher). The trial reports 8 study locations across 8 states.
The verdict
NCT06033950, a Phase 3 study of Heart Failure, is actively recruiting participants, sponsored by Colorado Prevention Center.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,600 participants
- Enrollment target
- 8
- Study locations
Study Summary
Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients with heart failure and reduced ejection fraction (HFrEF) who are intolerant or ineligible to receive treatment with steroidal mineralocorticoid receptor antagonists (sMRA).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Finerenone
Study Locations (8)
Alabama
- FIN-10004 Fairhope, AL Investigational Site - Fairhope
California
- FIN-10075 San Diego, CA Investigational Site - San Diego
Missouri
- FIN-10002 Kansas City, MO Investigational Site - Kansas City
Texas
- FIN-10015 Austin, TX Investigational Site - Austin
Goiás
- FIN-21003 Goiania, Goias Investigational Site - Goiânia
Sap Paulo
- FIN-21049 Sao Paulo, Investigational Site - Sao Paulp
São Paulo
- FIN-21004 Braganca Paulista, Investigational Site - Bragança Paulista
British Columbia
- FIN-11012 Surrey, BC Investigational Site - Surrey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,600 participants |
| Start Date | 2024-08-20 |
| Est. Completion | 2028-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06033950
The ClinicalTrials.gov registry entry for NCT06033950 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 2,600 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,042-participant average among 397 other Heart Failure trials with a reported enrollment target (27% higher). The listed sponsor is Colorado Prevention Center, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06033950 reports 8 study locations spanning 8 distinct geographic areas - top geographies include Alabama, California, Missouri.
Frequently Asked Questions
What is clinical trial NCT06033950 about?
NCT06033950 is a clinical study titled "A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists". Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients with heart failure and reduced ejection fraction (HFrEF) who are intolerant or ineligible to receive treatment with steroidal mineralocorticoid receptor antagonists (sMRA).
What is the current status of trial NCT06033950?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 2,600 participants. The study started on 2024-08-20. Estimated completion is 2028-04.
What conditions does trial NCT06033950 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT06033950?
The interventions under investigation include: Placebo (DRUG), Finerenone (DRUG).
Who is sponsoring clinical trial NCT06033950?
This trial is sponsored by Colorado Prevention Center, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06033950 being conducted?
This trial has 8 study locations across Alabama, California, Missouri, Texas, Goiás. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Home-based Cardiac Rehabilitation in Heart Failure
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)
RECRUITING · Phase 3
-
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
RECRUITING · Phase 3
-
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
RECRUITING · Phase 3
-
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.